development aspects
HHS Cancels $500 Million in BARDA-Funded mRNA Vaccine Contracts Amid Strategic Shift
HHS; BARDA; mRNA vaccine; vaccine development; contract cancellation; Robert F. Kennedy Jr.; COVID-19; federal funding; Moderna; Pfizer; Seqirus
ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals
ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development
FDA Reinstates Generic Drug Policy Group After April Firings
FDA; generic drugs; policy office; Division of Policy Development; reinstatement; layoffs; drug prices; administrative leave
Sanofi Announces $20 Billion US Investment Over Five Years
Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships
Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending
United States, Investments, Manufacture, Martes pennanti, Science, development aspects, Thermo Fisher
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects
HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments
GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness
Isomorphic Labs raises $600M to push AI-designed drugs into clinic
Isomorphous, Laboratory test finding, development aspects, AI-designed
Beyond Black Box: How Data-Driven AI Is Transforming RNA Medicine Development
Aortic Valve Insufficiency, development aspects, RNA medicine, black box, Data-Driven AI, Transforming RNA Medicine Development, datasets, Drug Design, Clinical Trials
MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results
MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns